Humanized mouse model of glucose 6-phosphate dehydrogenase deficiency for in vivo assessment of hemolytic toxicity

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 43, 2013, Pages 17486-17491

  Rochford, Rosemary ^a   Ohrt, Colin ^b   Baresel, Paul C ^a   Campo, Brice ^c   Sampath, Aruna ^b   Magill, Alan J ^b,f   Tekwani, Babu L ^d,e   Walker, Larry A ^d,e  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c Medicines for Malaria Venture   (Switzerland)

^d UNIVERSITY OF MISSISSIPPI   (United States)

^e UNIVERSITY OF MISSISSIPPI   (United States)

^f BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; DAPSONE; DOXYCYCLINE; MEFLOQUINE; PAMAQUINE; PRIMAQUINE; PYRIMETHAMINE; SITAMAQUINE; TAFENOQUINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD TOXICITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG SCREENING; ENGRAFTMENT; ERYTHROCYTE TRANSFUSION; FEMALE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HEMOLYSIS; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL;

AMINOQUINOLINES; ANEMIA, HEMOLYTIC; ANIMALS; ANTIMALARIALS; CHLOROQUINE; COMBINED MODALITY THERAPY; DAPSONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXYCYCLINE; DRUG EVALUATION, PRECLINICAL; ERYTHROCYTE COUNT; ERYTHROCYTE TRANSFUSION; FEMALE; GLUCOSEPHOSPHATE DEHYDROGENASE DEFICIENCY; HUMANS; MEFLOQUINE; MICE; MICE, INBRED NOD; MICE, SCID; PRIMAQUINE; PYRIMETHAMINE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TRANSPLANTATION, HETEROLOGOUS;

EID: 84886415336     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1310402110     Document Type: Article

References (39)

1. Nkhoma ET, Poole C, Vannappagari V, Hall SA, Beutler E (2009) The global prevalence of glucose-6-phosphate dehydrogenase deficiency: A systematic review and metaanalysis. Blood Cells Mol Dis 42(3):267-278.
2. Beutler E, Duparc S; G6PD Deficiency Working Group (2007) Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development. Am J Trop Med Hyg 77(4):779-789.
3. Baird JK, Hoffman SL (2004) Primaquine therapy for malaria. Clin Infect Dis 39(9): 1336-1345.
4. Brueckner RP, Ohrt C, Baird JK, Milhous WK (2001) 8-Aminoquinolines. Anti-malarial Chemotherapy: Mechanisms of Action, Resistance, and New Directions in Drug Discovery, ed Rosenthal P (Humana, Totowa, NJ).
5. White NJ (2008) The role of anti-malarial drugs in eliminating malaria. Malar J 7(Suppl 1):S8.
6. Wells TN, Burrows JN, Baird JK (2010) Targeting the hypnozoite reservoir of Plasmodium vivax: The hidden obstacle to malaria elimination. Trends Parasitol 26(3): 145-151.
7. White NJ (2013) Primaquine to prevent transmission of falciparum malaria. Lancet Infect Dis 13(2):175-181.
8. Shanks GD, et al. (2001) A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria. Clin Infect Dis 33(12):1968-1974.
9. Bosma MJ, Carroll AM (1991) The SCID mouse mutant: Definition, characterization, and potential uses. Annu Rev Immunol 9:323-350.
10. Shultz LD, Ishikawa F, Greiner DL (2007) Humanized mice in translational biomedical research. Nat Rev Immunol 7(2):118-130.
11. Davis PH, Stanley SL, Jr. (2003) Breaking the species barrier: Use of SCID mouse-human chimeras for the study of human infectious diseases. Cell Microbiol 5(12):849-860.
12. Thomsen M, Yacoub-Youssef H, Marcheix B (2005) Reconstitution of a human immune system in immunodeficient mice: Models of human alloreaction in vivo. Tissue Antigens 66(2):73-82.
13. Moore JM, Kumar N, Shultz LD, Rajan TV (1995) Maintenance of the human malarial parasite, Plasmodium falciparum, in SCID mice and transmission of gametocytes to mosquitoes. J Exp Med 181(6):2265-2270.
14. Ishihara C, et al. (1994) Transfusion with xenogeneic erythrocytes into SCID mice and their clearance from the circulation. J Vet Med Sci 56(6):1149-1154.
15. Moreno A, Badell E, Van Rooijen N, Druilhe P (2001) Human malaria in immunocompromised mice: New in vivo model for chemotherapy studies. Antimicrob Agents Chemother 45(6):1847-1853.
16. Tsuji M, Ishihara C, Arai S, Hiratai R, Azuma I (1995) Establishment of a SCID mouse model having circulating human red blood cells and a possible growth of Plasmodium falciparum in the mouse. Vaccine 13(15):1389-1392.
17. Badell E, et al. (2000) Human malaria in immunocompromised mice: An in vivo model to study defense mechanisms against Plasmodium falciparum. J Exp Med 192(11): 1653-1660.
18. Badell E, Pasquetto V, Eling W, Thomas A, Druilhe P (1995) Human Plasmodium liver stages in SCID mice: A feasible model? Parasitol Today 11(5):169-171.
19. Rajan TV, Moore JM, Shultz LD (1996) Immunodeficient mice as hosts for hemoparasitic infections. Parasitol Today 12(12):479-485.
20. Ishihara C, et al. (2003) Erythrocyte-replaced mouse model for Haemoparasite studies: Comparison of NOD/shi-scid and C.B-17/Jcl-scid mouse upon acceptability of human erythrocytes. J Vet Med Sci 65(8):831-837.
21. Angulo-Barturen I, et al. (2008) A murine model of falciparum-malaria by in vivo selection of competent strains in non-myelodepleted mice engrafted with human erythrocytes. PLoS ONE 3(5):e2252.
22. Vulliamy T, Beutler E, Luzzatto L (1993) Variants of glucose-6-phosphate dehydrogenase are due to missense mutations spread throughout the coding region of the gene. Hum Mutat 2(3):159-167.
23. Clyde DF (1981) Clinical problems associated with the use of primaquine as a tissue schizontocidal and gametocytocidal drug. Bull World Health Organ 59(3):391-395.
24. Beutler E (1996) G6PD: Population genetics and clinical manifestations. Blood Rev 10(1):45-52.
25. Beutler E (1969) Drug-induced hemolytic anemia. Pharmacol Rev 21(1):73-103.
26. Loiseau PM, Cojean S, Schrével J (2011) Sitamaquine as a putative antileishmanial drug candidate: From the mechanism of action to the risk of drug resistance. Parasite 18(2):115-119.
27. Tekwani BL, Walker LA (2006) 8-Aminoquinolines: Future role as antiprotozoal drugs. Curr Opin Infect Dis 19(6):623-631.
28. Elmes NJ, Nasveld PE, Kitchener SJ, Kocisko DA, Edstein MD (2008) The efficacy and tolerability of three different regimens of tafenoquine versus primaquine for postexposure prophylaxis of Plasmodium vivax malaria in the Southwest Pacific. Trans R Soc Trop Med Hyg 102(11):1095-1101.
29. Olteanu H, et al. (2012) High prevalence of Dapsone-induced oxidant hemolysis in North American SCT recipients without glucose-6-phosphate- dehydrogenase deficiency. Bone Marrow Transplant 47(3):399-403.
30. Vale N, Moreira R, Gomes P (2009) Primaquine revisited six decades after its discovery. Eur J Med Chem 44(3):937-953.
31. Beutler E (1959) The hemolytic effect of primaquine and related compounds: A review. Blood 14(2):103-139.
32. Cappellini MD, Fiorelli G (2008) Glucose-6-phosphate dehydrogenase deficiency. Lancet 371(9606):64-74.
33. Luzzatto L (2006) Glucose 6-phosphate dehydrogenase deficiency: From genotype to phenotype. Haematologica 91(10):1303-1306.
34. Bowman ZS, Jollow DJ, McMillan DC (2005) Primaquine-induced hemolytic anemia: Role of splenic macrophages in the fate of 5-hydroxyprimaquine-treated rat erythrocytes. J Pharmacol Exp Ther 315(3):980-986.
35. Greene S (1993) G6PD deficiency as protection against falciparum malaria: An epidemiologic critique of populations and experimental studies. Yearb Phys Anthropol, ed, Steegman A (Wiley-Liss, NY), pp 153-178.
36. Manganelli G, Masullo U, Passarelli S, Filosa S (2013) Glucose-6-phosphate dehydrogenase deficiency: Disadvantages and possible benefits. Cardiovasc Hematol Disord Drug Targets 13(1):73-82.
37. Akide-Ndunge OB, et al. (2009) Co-ordinated stage-dependent enhancement of Plasmodium falciparum antioxidant enzymes and heat shock protein expression in parasites growing in oxidatively stressed or G6PD-deficient red blood cells. Malar J 8:113.
38. Anonymous (2010) Guide for the Care and Use of Laboratory Animals (National Academy of Sciences) (National Academies Press, Washington, DC).
39. Bulliamy T, Luzzatto L, Hirono A, Beutler E (1997) Hematologically important mutations: Glucose-6-phosphate dehydrogenase. Blood Cells Mol Dis 23(2):302-313.